Physician profile
Ebon A Bourne
NPI 1225178825
$242,327.03
in general payments reported to CMS, 2019-2025
52 companies · $50K in 2025
The $50K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $24K · 2021: $21K · 2022: $52K · 2023: $40K · 2024: $28K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Consulting Fee: $13K · Travel and Lodging: $8,732 · Food and Beverage: $6,688 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $89,850.00 |
| Consulting Fee | $12,650.00 |
| Travel and Lodging | $8,731.90 |
| Food and Beverage | $6,687.76 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $225,778.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Eli Lilly and Company | $3,750.00 | 2023-2025 | |
| Amgen INC. | $1,531.63 | 2019-2025 | Evenity, Prolia, Repatha |
| Amarin Pharma, INC. | $1,323.73 | 2019-2022 | |
| Novo Nordisk INC | $1,245.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,099.72 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,052.96 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $646.31 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $643.73 | 2019-2022 | |
| Astellas Pharma US INC | $537.12 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $529.76 | 2019-2024 | Airsupra, Farxiga |
| Abbott Laboratories | $443.91 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.47 | 2019-2025 | Ofev, Jardiance |
| Janssen Pharmaceuticals, INC | $316.57 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $286.27 | 2019-2023 | Belsomra, Steglatro, Verquvo |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ebon Bourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.